This aligns with efforts by others to overcome immunotherapy resistance in MSS CRC, such as those by Liu et al., who showed that IL-17A inhibition enhances anti-PD-1 efficacy (37), and Wang H. et al., who identified GBP2 as a promising ICB combination target (8). Here, GBP2 is linked to colorectal carcinoma.